Role of PCSK9 in the course of ejection fraction change after ST‐segment elevation myocardial infarction: a pilot study

AIMS: Proprotein convertase subtilisin/kexin type 9 (PCSK9) has emerged as a therapeutic target for reducing plasma low‐density lipoprotein cholesterol. Beyond lipid control, recent findings suggest a deleterious effect of this protein in the pathogenesis of postmyocardial infarction left ventricle...

Descripción completa

Detalles Bibliográficos
Autores principales: Miñana, Gema, Núñez, Julio, Bayés‐Genís, Antoni, Revuelta‐López, Elena, Ríos‐Navarro, César, Núñez, Eduardo, Chorro, Francisco J., López‐Lereu, Maria Pilar, Monmeneu, Jose Vicente, Lupón, Josep, Sanchis, Juan, Bodí, Vicent
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2020
Materias:
Original Research Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7083416/
https://www.ncbi.nlm.nih.gov/pubmed/31903686
http://dx.doi.org/10.1002/ehf2.12533

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7083416/
https://www.ncbi.nlm.nih.gov/pubmed/31903686
http://dx.doi.org/10.1002/ehf2.12533

Ejemplares similares